Loading clinical trials...
Loading clinical trials...
A Phase Ib Trial on the Safety and Feasibility of Neoadjuvant Low Dose Radiation, Chemotherapy and Durvalumab for Potentially Resectable Stage III Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Durvalumab
nanoparticle albumin bound paclitaxel
+1 more
Locations
1
China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Start Date
June 10, 2021
Primary Completion Date
June 10, 2023
Completion Date
June 10, 2023
Last Updated
December 15, 2021
NCT06917573
NCT05468242
NCT01993810
NCT03154190
NCT03492801
NCT03229278
Lead Sponsor
Juan LI, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions